Skip to content

MARS MRI in Revision THA With a Ceramic Femoral Head and Titanium Sleeve

Metal Artifact Reduction Sequence MRI in Revision Total Hip Arthroplasty With a Ceramic Femoral Head and Titanium Sleeve

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05686915
Enrollment
55
Registered
2023-01-17
Start date
2022-12-22
Completion date
2023-12-31
Last updated
2023-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty, Replacement, Hip

Keywords

Revision, Titanium Sleeve

Brief summary

Revision total hip replacement using a ceramic head utilizes a titanium sleeve which introduced another articulation into the system that may lead to a local soft tissue reaction. The purpose of this study is to determine the frequency, size and types of MRI documented local tissue reactions in individuals doing well after a revision total hip replacement and ceramic bearing surface that utilizes a titanium sleeve.

Detailed description

Metal-on-metal total hip arthroplasty (THA) were heralded as a solution for two of the most common problems in hip arthroplasty in the last decade, instability and osteolysis. Unfortunately, their failures have led to diminished enthusiasm for this bearing surface. Adverse local tissue reactions (ATLRs) have been well documented as a means of pain and failure in this population. A recent report revealed that the most commonly used bearing surface in total hip arthroplasty, metal-on-polyethylene, may have up to a 28% incidence of MRI abnormalities in asymptomatic hips. Revision THA using a ceramic head utilizes a titanium sleeve which introduced another articulation into the system that may lead to a local soft tissue reaction. The purpose of this study is to determine the frequency, size and types of MRI documented local tissue reactions in asymptomatic individuals after a revision THA and ceramic bearing surface that utilizes a titanium sleeve. To our knowledge, this has not been studied previously and may provide important baseline features of this diagnostic tool with this particular bearing surface. We hypothesize that there will be fluid collections in a small but clinically significant portion of asymptomatic patients.

Interventions

DIAGNOSTIC_TESTMARS MRI

metal artifact reduction sequence (MARS) MRI to assess for fluid collections, ATLRs or other abnormalities

DIAGNOSTIC_TESTTitanium Labs

Labs to look at titanium levels in blood

DIAGNOSTIC_TESTCobalt Labs

Labs to look at cobalt levels in blood

DIAGNOSTIC_TESTChromium Labs

Labs to look at chromium levels in blood

Sponsors

Colorado Joint Replacement
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Patients who received a revision total hip surgery utilizing a ceramic femoral head with a titanium sleeve * Patient whose age ranges from 18-99 * Patients who are not experiencing groin pain, thigh pain, or pain with ROM of the hip * Patients who are at least 2 years after a revision THA * Acetabular implant (cup) was placed in the appropriate position * Patients with a Harris Hip Score of \>90

Exclusion criteria

* Patients who do not meet the above criteria * Patients unable to have an MRI (i.e. pacemaker, metal implants or issues with claustrophobia requiring sedation)

Design outcomes

Primary

MeasureTime frameDescription
MARS MRI abnormalities2 Years Post Revision Total Hip ReplacementLocal Tissue Reactions or Fluid collections on the MARS MRI Scan

Secondary

MeasureTime frameDescription
Titanium Lab Value2 Years Post Revision Total Hip ReplacementTitanium levels in blood
Chromium Lab Value2 Years Post Revision Total Hip ReplacementChromium levels in blood
Cobalt Lab Value2 Years Post Revision Total Hip ReplacementCobalt levels in blood

Countries

United States

Contacts

Primary ContactRoseann M Johnson, BS, CCRP
roseannjohnson@centura.org303-260-2940

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026